

January 2011

**ANNUAL DECLARATION OF INTERESTS  
GLOBAL INITIATIVE FOR ASTHMA: SCIENCE COMMITTEE  
1 January 2010 – December 2010**

GINA Committee members disclose relationships (personal benefits, shares, and non-personal interests) with profit-making organizations each year using the following definitions.

- 1. *Personal Benefits*** refers to fees for lectures, advisory committees or consultancy services either intermittent or regular, from which a GINA member benefits personally. This includes ongoing attendance at advisory board meetings.
- 2. *Shares*** refers to any shares in the pharmaceutical industry, excluding unit trusts, pension plans or mutual funds, and it refers to shares held by a GINA member or family members (spouse/dependent children < 18 yrs). The company is to be listed, not the number of shares.
- 3. *Non-Personal Interests*** refers to fees or grants paid to a GINA Committee member (or the Department/Institution on behalf of a GINA member) and used for research, education, equipment, salaries, etc.

For each category, items are included in one of two categories: payment or service is valued in excess of \$1,000 (US) but less than \$10,000 and payment or service is valued in excess of \$10,000. The information disclosed by each member of the GINA Executive Committee for the year 2009 is presented in an effort to be as transparent as possible. For more complete background about this process, see “Annual Declaration of Interests: Global Initiative for Asthma (GINA)” on the website at: <<http://www.ginasthma.org>>.

**SUMMARY FOR YEAR 2010:**

**Allan Becker, Winnipeg, Manitoba, Canada:** *Personal Benefits* <\$10,000: AstraZeneca, Graceway, Merck Sharp & Dohme, Nycomed. *Shares*: none. *Non-Personal Interests* >\$10,000: AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme.

**Peter Barnes, London, England:** *Personal Benefits* >\$10,000: AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis, Nycomed, Pfizer, RespiVert. *Shares*: none. *Non-Personal Interests* >\$10,000: Aquinox, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Nycomed, Pfizer.

**Neil Barnes, London England:** *Personal Benefits* <\$10,000: AstraZeneca, Chiesi, Novartis, Teva. *Personal Benefits* >\$10,000: GlaxoSmithKline, Nycomed. *Shares*: none. *Non-Personal Interests* >\$10,000: GlaxoSmithKline, Merck Sharp & Dohme, Novartis.

**Eric Bateman, Capetown, South Africa:** *Personal Benefits* <\$10,000: Actelion, ALKAbello, Ammirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Elevation Pharma, Forest, GlaxoSmithKline, Hoffman LaRoche, Merck Sharp & Dohme, Novartis, Nycomed, Pfizer. *Shares*: none. *Non-Personal Interests*: none.

**Johan de Johgste, Rotterdam, Netherlands:** *Personal Benefits*: none. *Shares*: none. *Non-Personal Interests* <\$10,000: GlaxoSmithKline.

**Jeffrey M. Drazen, Boston Massachusetts US:** *Personal Benefits* none. *Shares:* none. *Non-Personal Interests:* none.

**Mark FitzGerald, Vancouver, British Columbia, Canada:** *Personal Benefits* <\$10,000: Boehringer-Ingelheim, Novartis, Nycomed. *Personal Benefits* >\$10,000: AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme. *Shares:* none. *Non-Personal Interests* >\$10,000: Boehringer Ingelheim, Canadian Institute for Health Research, Genentech, GlaxoSmithKline, Medimmune, Novartis, Pharmaxis, Topigen, Wyeth.

**Robert Lemanske, Madison, Wisconsin USA:** *Personal Benefits* < \$10,000: American Institute of Research, Elsevier, GlaxoSmithKline, Michigan Public Health Institute, Merck Sharp & Dohme, Inc., SA Boney and Associates, LTD, Sepracor, UpToDate. *Shares:* none. *Non-Personal Benefits:* none.

**Paul O'Byrne, Hamilton, Ontario, Canada:** *Personal Benefits* <\$10,000: Abbott, Asmacure, Chiesi, GlaxoSmithKline, Merck Sharp & Dohme. Wyeth. *Personal Benefits* >\$10,000: AstraZeneca. *Shares:* none. *Non-Personal Interests* >\$10,000: Asmacure, Acetelion, AstraZeneca, Genentech, Wyeth.

**Ken Ohta, Tokyo, Japan:** *Personal Benefits* <\$10,000: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, IE Kyorin, Merck Sharp & Dohme, Novartis. *Shares:* none. *Non-Personal Interests:* none.

**Soren Pedersen, Kolding, Denmark:** *Personal Benefits* <\$10,000: GlaxoSmithKline, Nycomed. *Shares:* none. *Non-Personal Interests* <\$10,000: AstraZeneca.

**Emilio Pizzichini, Florianópolis – SC Brazil:** *Personal Benefits* <\$10,000: AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis, Nycomed. *Shares:* none. *Non-Personal Interests:* none.

**Helen K. Reddel, Camperdown Australia:** *Personal Benefits* <\$10,000: AstraZeneca, Biota, GlaxoSmithKline, Merck Sharp & Dohme, Novartis. *Personal Benefits* >\$10,000: AstraZeneca, Novartis. *Shares:* none. *Non-Personal Interest* >\$10,000: GlaxoSmithKline.

**Sally E. Wenzel, Pittsburgh, Pennsylvania US:** *Personal Benefits* < \$10,000: Array, J&J, Genentech. *Shares:* Amira. *Non-Personal Interests* >\$10,000: Amgen, GlaxoSmithKline, MedImmune, Sanofi-Aventis.